EUVIMEDEUVIMED entdecken
Vergleichsstudie

Newly defined clinical obesity versus body mass index ‐defined obesity: Differential risks of overall death and adverse events in a population‐based cohort

Li-You Lian, Chuan Liu, Xiao-Dong Zhou iD, Giovanni Targher iD, Christopher D Byrne iD, Yilin Zhang, Xiaolong Qi, Hui Jin, Ming-Hua Zheng iD, Wen-Yue Liu

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.70271 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Li-You Lian und 9 weiteren Autor:innen. Beteiligte Einrichtung: MAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. Hauptthemen laut MEDLINE: Body Mass Index, Obesity, Cardiovascular Diseases. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To compare the prognostic implications of the newly proposed clinical obesity classification against traditional body mass index ( BMI) ‐defined obesity in a population‐based cohort. Materials and Methods Using UK Biobank, we compared the impact of newly defined obesity, including clinical obesity (obesity status with obesity‐related comorbidities) and pre‐clinical obesity (obesity status with preserved organ function), with traditional BMI ‐defined obesity on death, cardiovascular disease ( CVD ), chronic kidney disease ( CKD ), and liver‐related events ( LREs ). To further delineate heterogeneity within the clinical obesity group, we performed stratified analyses based on comorbidity burden (number of comorbidities), severity of adiposity, and presence of diabetes or hypertension.

Results

A total of 502 129 participants were enrolled. About 375 585 (74.8%) had non‐obesity, 126 544 (25.2%) had BMI ‐defined obesity (including 93 410 [73.8%] with clinical obesity and 13 875 [11.0%] with pre‐clinical obesity). During a median follow‐up of 15.8 years, clinical obesity was associated with significantly higher risks of death ( HR = 1.097, 95% CI : 1.071–1.125, p < 0.001), LRE ( HR = 1.103, 95% CI : 1.040–1.169, p < 0.001), CVD ( HR = 1.118, 95% CI : 1.091–1.146, p < 0.001), and CKD ( HR = 1.111, 95% CI : 1.081–1.141, p < 0.001) compared to BMI ‐based obesity. Conversely, pre‐clinical obesity showed significantly lower risks across these outcomes. High‐risk clinical obesity subgroups with multiple comorbidities or severe adiposity showed particularly increased risks.

Conclusion

The clinical obesity classification helps to define a high‐risk phenotype with substantially increased risks of mortality and major comorbidities, while pre‐clinical obesity defines a distinct subgroup with more favourable outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Body Mass IndexObesityCardiovascular DiseasesHumansFemaleMaleMiddle AgedAgedComorbidityUnited KingdomRisk FactorsRenal Insufficiency, ChronicCohort StudiesAdultPrognosisLiver Diseases

Stichwörter der Autor:innen

cardiovascular diseasechronic kidney diseaseclinical obesityliver‐related eventsobesity

Autor:innen und Institutionen

  • MAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Institute of Hepatology, Wenzhou Medical University, Wenzhou, China.
  • Key Laboratory of Diagnosis and Treatment for the Development of Chronic Liver Disease in Zhejiang Province, Wenzhou, China.
  • Liver Disease Center of Integrated Traditional Chinese and Western Medicine, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nurturing Center of Jiangsu Province for State Laboratory of…
  • Basic Medicine Research and Innovation Center of Ministry of Education, Zhongda Hospital, Southeast University.
  • State Key Laboratory of Digital Medical Engineering, Nanjing, China.

ORCID-Profile: Xiao-Dong Zhou, Giovanni Targher, Christopher D Byrne, Ming-Hua Zheng

Förderung

  • National Natural Science Foundation of China
  • National Key Research and Development Program of China

Zitieren

APA

Lian, L. Y., Liu, C., Zhou, X. D., Targher, G., Byrne, C. D., Zhang, Y., Qi, X., Jin, H., Zheng, M. H., & Liu, W. Y. (2026). Newly defined clinical obesity versus body mass index ‐defined obesity: Differential risks of overall death and adverse events in a population‐based cohort. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70271

Vancouver

Lian LY, Liu C, Zhou XD, Targher G, Byrne CD, Zhang Y, et al. Newly defined clinical obesity versus body mass index ‐defined obesity: Differential risks of overall death and adverse events in a population‐based cohort. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70271

BibTeX
@article{Lian2026,
  author = {Lian, Li-You and Liu, Chuan and Zhou, Xiao-Dong and Targher, Giovanni and Byrne, Christopher D and Zhang, Yilin and Qi, Xiaolong and Jin, Hui and Zheng, Ming-Hua and Liu, Wen-Yue},
  title = {Newly defined clinical obesity versus body mass index ‐defined obesity: Differential risks of overall death and adverse events in a population‐based cohort},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.70271}
}
Kostenlos starten →